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Gene Expression Meta‐Analysis Reveals Concordance in 
Gene Activation, Pathway, and Cell‐Type Enrichment in 
Dermatomyositis Target Tissues
Jessica Neely,  Dmitry Rychkov, Manish Paranjpe, Michael Waterfield, Susan Kim, and Marina Sirota
Objective. We conducted a comprehensive gene expression meta‐analysis in dermatomyositis (DM) muscle and 
skin tissues to identify shared disease‐relevant genes and pathways across tissues.
Methods. Six publicly available data sets from DM muscle and two from skin were identified. Meta‐analysis 
was performed by first processing data sets individually then cross‐study normalization and merging creating 
tissue‐specific gene expression matrices for subsequent analysis. Complementary single‐gene and network analyses 
using Significance Analysis of Microarrays (SAM) and Weighted Gene Co‐expression Network Analysis (WGCNA) 
were conducted to identify genes significantly associated with DM. Cell‐type enrichment was performed using xCell.
Results. There were 544 differentially expressed genes (FC ≥ 1.3, q < 0.05) in muscle and 300 in skin. There were 94 
shared upregulated genes across tissues enriched in type I and II interferon (IFN) signaling and major histocompatibility 
complex (MHC) class I antigen‐processing pathways. In a network analysis, we identified eight significant gene modules 
in muscle and seven in skin. The most highly correlated modules were enriched in pathways consistent with the single‐
gene analysis. Additional pathways uncovered by WGCNA included T‐cell activation and T‐cell receptor signaling. In 
the cell‐type enrichment analysis, both tissues were highly enriched in activated dendritic cells and M1 macrophages.
Conclusion. There is striking similarity in gene expression across DM target tissues with enrichment of type I and 
II IFN pathways, MHC class I antigen‐processing, T‐cell activation, and antigen‐presenting cells. These results sug-
gest IFN‐γ may contribute to the global IFN signature in DM, and altered auto‐antigen presentation through the class 
I MHC pathway may be important in disease pathogenesis.
INTRODUCTION
Dermatomyositis (DM) is an idiopathic inflammatory myopa-
thy (IIM) distinguished from other IIMs by pathognomonic skin 
rashes. Prior gene expression studies have identified a type 
I interferon (IFN) signature in the muscle, skin, and peripheral 
blood of patients with juvenile and adult DM (1–3), suggesting 
its potential role in disease pathogenesis. In addition, the type I 
IFN signature appears to correlate with disease activity (4,5), and 
early data from a clinical trial of sifalimumab, an IFN‐α antago-
nist, demonstrated neutralization of the IFN signature with treat-
ment and more clinical improvement in subjects with greater IFN 
reduction (6). DM also shares overlapping clinical features with 
other type I IFN‐mediated diseases, including systemic lupus 
erythematosus (SLE) and the monogenic interferonopathies, 
STING‐associated vasculopathy (7), and chronic atypical neutro-
philic dermatosis (CANDLE) (8). These observations suggest that 
type I IFN is important in disease pathogenesis. However, whether 
dysregulated type I IFN signaling is the primary cause of disease 
or secondary to another immune‐ or nonimmune‐mediated 
mechanism remain unknown, and less is known about alternative 
immune pathways that may underlie the IFN response.
Recently, more attention has been paid to the role of type 
II IFN in IFN‐mediated diseases, including in SLE and DM. Type 
I IFN, which includes IFN‐α and IFN‐β, is primarily secreted by 
dendritic cells and macrophages and is involved in the innate 
and antiviral response, whereas type II IFN, or IFN‐γ, is secreted 
by T and NK cells and is important for linking innate and adaptive 
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immune responses. Using a modular approach to deconstruct 
the IFN signature in SLE, Chiche et  al identified three distinct 
IFN modules expressed in the peripheral blood of SLE patients, 
which were each activated in stepwise fashion (9). The first IFN 
module was stable over the disease course and consisted of 
genes induced primarily by type I IFN, whereas the second and 
third IFN modules correlated with skin and renal disease activity, 
and the genes in these modules were equally induced by both 
types I and II IFN, suggesting a role for type II IFN in SLE. In juve-
nile DM, IFN‐γ transcripts have been identified in the muscle tis-
sue of 11 untreated patients and co‐localized with inflammatory 
infiltrates and T cells (10). However, the role of type II IFN in DM 
has not been thoroughly explored using unbiased, data‐driven 
methods.
The rarity of DM limits the feasibility of well‐powered stud-
ies, making data‐driven translational studies challenging. Com-
putational methods allow researchers to integrate historical 
data sets from different research groups using methods that 
are robust to different assay technologies as an approach to 
overcome these challenges. Gene expression meta‐analysis is 
a strategy used to increase sample size by combining diverse 
data sets developed on different platforms, which increases the 
power to detect differentially expressed genes and discover 
new biological insights. Furthermore, studying gene expression 
in the target tissues of a disease strengthens the association 
of results when findings are shared between tissues and also 
allows for comparison of tissue‐specific gene expression. This 
approach has been applied to the study of gene expression in 
rheumatoid arthritis comparing synovial fluid and blood (11), as 
well as in antineutrophil cytoplasmic antibody–associated vas-
culitis comparing orbital tissue, peripheral blood leukocytes, 
and sinus brushings (12).
The purpose of this study was to conduct a comprehen-
sive gene expression meta‐analysis leveraging publicly available 
microarray data sets to identify novel gene signatures expressed 
in DM muscle and skin using hypothesis‐free methods. Because 
skin and muscle disease may follow a discordant clinical course 
in DM, a secondary objective of this study was to compare gene 
signatures across tissues to determine if immune pathways are 
shared across tissues and identify unique immune pathways that 
might explain these clinical observations. Refining our knowledge 
of the dysregulated immune pathways in target tissues in DM is 
critical to advancing biomarker and drug development for this rare 
and understudied disease and challenging disease paradigms 
leading to new mechanistic hypotheses.
METHODS
Gene expression meta‐analysis pipeline. An over-
view of the pipeline is presented in Figure 1. Publicly available 
microarray data sets from Gene Expression Omnibus (GEO) 
(13) were searched for the key words “myositis” and “dermato-
myositis.” These samples were curated to include only subjects 
with dermatomyositis, including both adult and juvenile sub-
types. All other myositis subtypes were excluded. Any sam-
ples annotated as inactive disease or nonlesional skin were 
excluded. Additional clinical covariates, including age, sex, 
treatment status, and duration of disease, were not available 
for all samples and thus, in order to avoid introducing false pos-
itives from imputation, were not included. Age was annotated 
for 93% of muscle samples, of which 44% were pediatric. All 
skin samples were from adult subjects. In muscle, sex was 
annotated in 77% of samples of which 88% were female, and 
in skin, sex was known for all samples, of which 66% were 
female.
Raw data were downloaded for each data set and pro-
cessed. The processing steps included background correction, 
log2 transformation, quantile normalization, and probe to gene 
mapping using R language (14) v3.5.2. We used the R pack-
age, SCAN.UPC (15) from Bioconductor (16) to process the 
data from Affymetrix platforms and the BrainArray database (17) 
v22 to map probes to Entrez gene IDs. For GSE32245 from 
the Stanford platform, we used the limma package v3 (18) to 
perform processing steps and mapped probes to genes using 
GPL files. For GSE3307, the data from A and B arrays were 
merged using the mean intensities of common probes. Once 
processed, all muscle data sets were merged in accordance 
with the previously published pipeline by Hughey and Butte (19). 
During this step, the expression data were mean centered and 
reduced to the number of common probes across all data sets. 
Cross‐study normalization was performed with ComBat within 
sva package v3 (20). Principle component analysis (PCA) plots 
and boxplots were used to evaluate for successful batch correc-
tion and to detect outliers using three standard deviations of the 
first two principal components. One sample, GSM799008 from 
GSE32245, was recognized as an outlier and removed from the 
analysis.
Differential gene expression: Significance Analysis 
of Microarrays. Significance Analysis of Microarrays (SAM), 
implemented in the R package siggenes v1.56 (21), was used 
to determine differentially expressed genes between cases and 
controls in each tissue using a cutoff false discovery rate (FDR) 
(22) q value of less than 0.05 and fold change (FC) of 1.3 or 
more. Unsupervised hierarchical clustering using the Ward algo-
rithm (23) was used to generate heatmaps. Significant overlap 
between up‐ and downregulated genes between muscle and 
skin was assessed using a hypergeometric test. Functional 
enrichment analysis of gene lists was carried out by overrep-
resentation analysis using the ReactomePA package v1.26 (24), 
which detects enrichment of Reactome Database (25) pathway 
terms. The P values were calculated from the hypergeometric 
distribution and controlled for multiple comparisons using the 
Benjamini‐Hochberg method.
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Network analysis: Weighted Gene Co‐Expression 
Network Analysis. In order to detect associations that were 
not identified on the single gene level, network analysis was 
performed using Weighted Gene Co‐Expression Network 
Analysis (WGCNA) v1.68 (26,27). Muscle and skin coexpres-
sion networks were each constructed using step‐by‐step 
signed network construction followed by module detection. 
In this context, a module is defined as a highly connected set 
of genes that are positively or negatively correlated. We then 
calculated the significance between the module eigengene, 
or first principal component in the module, and case/control 
status. To compare muscle and skin networks, we calculated 
the significance of the gene overlap between each muscle and 
skin module using a hypergeometric test adjusting P values 
for multiple comparisons. Additionally, network preservation 
statistics were computed with a module Z‐summary score 
with a Z‐summary greater than 10 considered to be strong 
evidence of preservation in the corresponding network and a 
score less than 10 but greater than 2 considered to be weak 
to moderate evidence of network preservation as previously 
described (28).
Within the significant modules, we identified hub genes. A 
hub gene is a highly connected gene likely to be of biological 
significance and defined as a gene significance (a measure of 
how biologically significant each gene is in the network) greater 
than 0.2 and module membership (how connected a gene is 
to all the other genes in the module) greater than 0.8 (26). 
Module enrichment was evaluated using ReactomePA v1.26 
and clusterProfiler R packages v3.10 (29). Network visualiza-
tion using the STRING v10 database (30) was used to assess 
evidence for protein‐protein interactions between these hub 
genes.
Figure 1. Gene expression meta‐analysis pipeline. Abbreviations: GEO, Gene Expression Omnibus; SAM, Significance Analysis of Microarrays; 
FC, fold change; DEG, differentially expressed genes; WGCNA: Weighted Gene Coexpression Network Analysis.
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Cell‐type enrichment analysis. Enrichment of cell 
types was determined with xCell v1.1 (31). Cell types were 
filtered to remove erythrocytes, epithelial cells, and stromal 
cells because they are not relevant to our analysis, resulting 
in total of 42 immune cell types. Significance assessment to 
determine the likelihood the cell type is in the mixture was 
calculated using predefined beta distribution parameters 
from random mixtures generated from the reference data 
sets in xCell (31). A t test was used to determine differential 
cell enrichment between cases and controls using a thresh-
old of P < 0.01. The false discovery rate was controlled by 
the Benjamini‐Hochberg method. Significantly differentially 
enriched cell types were visualized with hierarchical clustering 
using the Ward algorithm.
The IFN signature. The upregulated gene lists identified 
by SAM were uploaded into Interferome v2.0 (32) to determine 
whether genes were influenced by type I or type II IFN signaling. 
Interferome is a database of curated results from experiments 
assessing the IFN response in vitro and in vivo. For our pur-
poses, the reference data set was filtered to only include prior 
experiments performed in vivo in human disease states.
RESULTS
A total of six microarray data sets from muscle tissue and 
two from skin tissue were identified. After curation and removal 
of one outlier in the skin data set, a total of 107 samples from 
muscle and 99 samples from skin were included. The number 
of samples from cases and controls is shown in Figure 1. All 
studies (1,3,33–35) included are displayed in Supplementary 
Table 1. Studies were successfully merged and batch‐cor-
rected as visualized by PCA plots displayed in Supplementary 
Figure S1. The expression matrices contained 11 703 com-
mon genes in the merged muscle data set and 17 418 com-
mon genes in the merged skin data set.
Single gene analysis reveals overlap of upreg-
ulated genes enriched in IFN responses. In the sin-
gle‐gene analysis, 544 genes were significantly differentially 
expressed between cases and controls in muscle, of which 
443 were upregulated and 101 were downregulated (FC ≥ 
1.3, q < 0.05; Figure  2A). In skin, 300 genes were differen-
tially expressed, of which 214 were upregulated and 86 were 
downregulated (Figure  2B). There was significant overlap by 
the hypergeometric test in the upregulated genes across skin 
and muscle with a total of 94 shared genes, P = 6.4xE−78 (see 
Supplementary Table 2 for the full gene list). Many of these 
genes were IFN‐stimulated genes (ISGs), including CXCL10, 
RSAD2, ISG15, IFI44L, IFIT3, IF44, and MX1 being the most 
strongly expressed across both tissues (Figure  3A). There 
was no significant overlap in repressed genes with only two 
shared genes, DDX3Y and RPS4Y1, both expressed on the Y 
chromosome. Enrichment of the 94 overlapping upregulated 
genes revealed several pathways involved in both innate and 
adaptive immune responses (Figure  3B). The most enriched 
terms, consistent with prior gene expression studies, were 
related to type I IFN signaling. However, several other themes 
emerged, including type II IFN signaling, class I mediated 
antigen‐processing and presentation, chemokine signaling, 
and complement activation.
Analysis of the tissue‐specific upregulated gene lists 
revealed significant overlap in the enriched pathways of both 
gene sets as well. Significantly enriched terms in both gene 
Figure 2. Heatmaps of differentially expressed genes identified by Significance Analysis of Microarrays (SAM). Hierarchical clustering of 
significant differentially expressed genes (DEGs) in muscle (A) and skin (B) using the cutoff of the false discovery rate P value < 0.05 and fold 
change ≥ 1.3 demonstrates clustering of cases and controls and that the majority of DEGs in both tissues are upregulated.
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lists were type I IFN signaling, type II IFN signaling, and terms 
related to class I major histocompatibility complex (MHC) 
antigen‐processing pathways. Complement activation and 
interleukin (IL) signaling were pathways uniquely enriched in 
skin, whereas neutrophil degranulation, extracellular matrix 
organization, collagen formation, and MHC class II antigen 
processing and presentation were terms uniquely enriched in 
muscle. A network map of the most enriched terms in each 
tissue and the differentially expressed genes identified by SAM 
is displayed in Figure  4, demonstrating the interconnected-
ness of these pathways on the gene level and emphasizing 
the network similarity between muscle and skin. Enrichment 
Figure 3. There are 94 overlapping genes in muscle and skin enriched in common immune pathways. A, Gene symbols of 94 overlapping 
differentially expressed genes plotted by fold change in muscle and skin. B, Enrichment of 94 overlapping genes by overrepresentation analysis 
using the Reactome Database. P values are calculated using a hypergeometric distribution and corrected for multiple comparisons by the 
Benjamini‐Hochberg method.
Figure 4. Network maps demonstrating the most enriched terms in each tissue, muscle (A) and skin (B), and the upregulated genes found to 
be differentially expressed acting in these pathways. These maps demonstrate the interrelatedness of many of these immune pathways in both 
tissues and highlight the similarity of genes and pathways across the two tissues.
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of downregulated gene lists revealed repression of glucose 
metabolism in muscle and repression of fatty acid and steroid 
metabolism in skin.
Network analysis identifies overlapping gene mod-
ules between muscle and skin and enrichment of terms 
related to T‐cell activation. By applying WGCNA to the 
merged gene expression matrices from each tissue, we identified 
eight modules in muscle and seven modules in skin that met our 
significance threshold and were either positively or negatively cor-
related to case/control status (see Figure 5A). At least one module 
in each tissue‐specific network had significant overlap on the gene 
level assessed by a hypergeometric test with one or more modules 
in the other network, as indicated by the asterisks in Figure 5A. 
Hierarchical clustering of these gene modules revealed clustering 
of both upregulated and downregulated modules. A concentrated 
cluster of modules highly correlated with DM cases in both muscle 
and skin networks consisted of the M1 and M3 modules along 
with the S1 and S3 modules (denoted by the green box in Fig-
ure 5A). These modules were also the highly preserved modules 
by network preservation statistics (28) in both networks reaching 
Z‐summary scores greater than 10 (Supplementary Table 3).
Enrichment analysis of these specific modules (M1, M3, S1, 
and S3) using the Reactome Pathway database revealed enrich-
ment of immune pathways relevant to disease that was consistent 
with those identified in the single‐gene analysis, including type I 
and II IFN signaling, class I MHC antigen processing and pres-
entation, and chemokine signaling (Figure 5B). However, several 
additional pathways not seen on the single‐gene level were also 
enriched. Most notably, in the M3 and S1 modules, there were 
several pathways enriched relating to T‐cell activation, including 
CD28 co‐stimulation, IL‐2 signaling, and T‐cell receptor signaling 
events (Figure  5B). There were also signs of immunoregulatory 
signaling pathways, including PD‐1 signaling and IL‐10 signaling 
in both networks. Unique to the muscle network, the M1 mod-
ule was also enriched in the unfolded protein response. Although 
there was no overlap of pathway enrichment in the single‐gene 
analysis, we did find overlap on the network level between the M8 
and S6 module. These modules were both enriched in processes 
related to energy metabolism, including the citric acid cycle, res-
piratory electron transport chain, adenosine triphosphate synthe-
sis, and fatty acid metabolism.
There were 615 hub genes in the muscle network and 271 
hub genes in the skin network identified as meeting the criteria 
of module membership greater than 0.2 and gene significance 
greater than 0.8. The top hub genes in each network were from 
the M1 module in muscle as well as the S1 module in skin, con-
sistent with the fact that these modules were most strongly corre-
lated with case/control status. The 30 most significant hub genes 
are displayed in Supplementary Table 4. These genes are likely to 
Figure 5. A, Heatmap demonstrating hierarchical clustering of significant modules identified by WGCNA in each tissue based on gene 
overlap. Correlation between module eigengene and disease status, sign*(correlation), is shown by the red to blue bar, where red represents 
modules most positively correlated with cases and blue represents modules negatively correlated with cases. The ‐log10 adjusted P value of 
this correlation is indicated by the yellow to orange bar. The degree of pairwise overlap in genes between muscle modules and skin modules 
computed using a hypergeometric test is denoted by grey coloring where modules with significant overlap in genes (P < 0.05) are denoted 
by an asterisk and the color range corresponds to –log10(P value) of the pairwise overlap. B, Enrichment of pathways from the Reactome 
database across a cluster of highly overlapping and interesting modules in each tissue (green box in pane A) demonstrating enrichment of 
shared pathways across tissues. P values are adjusted for comparisons across modules by the Benjamini‐Hochberg method.
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be of high biological relevance within each network and include 
several of the same genes identified in the single‐gene analysis, 
including genes classically upregulated by type I IFN (STAT1, 
MX1, IFI44, ISG15), genes classically upregulated by type II IFN 
(CXCL10 and GBP1), genes involved in class I MHC antigen pro-
cessing (HLA‐A, ‐B and ‐F, B2M, TAP1), and immunoproteasome 
genes (PSMB8 and PSMB9). There was strong evidence for inter-
actions between the proteins encoded by these overexpressed 
genes in the STRING database, and network visualization for the 
top 50 hub genes in each network are included in Supplementary 
Figure S2.
Cell‐type enrichment analysis identifies antigen‐
presenting cells as the most enriched cell type in both 
tissues. A total of 42 immune cell types were evaluated by cell‐
type enrichment analysis using xCell. Nineteen of these cell types 
were significantly enriched in muscle, and 20 cell types were sig-
nificantly enriched in skin. Hierarchical clustering showed sepa-
ration of cases and controls, with cases being most significantly 
enriched in antigen‐presenting cells, including activated dendritic 
cells and other dendritic cell types and classically activated M1 
macrophages (Figure 6). There was also enrichment of CD4+ and 
CD8+ T cells as well as gamma‐delta (γδ) T cells; however, there 
was no enrichment of B cells. Interestingly, regulatory T cells were 
enriched in cases in skin, whereas these cells were enriched in 
controls in muscle tissue.
The DM IFN signature is enriched for IFN‐stimulated 
genes induced by both type I and type II IFN. The upregu-
lated gene lists for each tissue were uploaded to Interferome v2.0 
to determine whether the ISGs identified in our gene lists were 
influenced by type I or type II IFN based on curated results of 
previous studies measuring the in vivo IFN response in human dis-
ease states. The majority of ISGs in both tissues were stimulated 
by both type I and type II IFN. In muscle,133 genes were classified 
as ISGs, of which 14 were exclusively stimulated by type I IFN, 
whereas, 119 were stimulated by both type I and type II IFN. A 
similar observation was seen in the skin gene list where 124 genes 
were classified as ISGs, of which only 4 were exclusively stimu-
lated by type I IFN, whereas the other 120 were induced by both 
type I and type II IFN. Interestingly, two genes previously identified 
as markers to differentiate type II from type I IFN responses (36), 
GBP1 and GBP2, were significantly upregulated in our analysis: 
both GBP1 and GBP2 were upregulated in muscle, and GBP1 
was upregulated in skin in the single‐gene analysis. In the network 
analysis, both GBP1 and GBP2 were highly coexpressed in the 
most significantly upregulated modules in both networks, provid-
ing further evidence that IFN‐γ may contribute to the global IFN 
signature in DM target tissues.
DISCUSSION
Gene expression meta‐analysis is a powerful method for 
identifying new biological insights of rare, complex diseases 
that can be explored with future functional studies. This analysis 
demonstrates, through both single‐gene and network analyses, 
the presence of shared transcriptomic signatures across muscle 
and skin tissues in DM and simultaneous activation of innate and 
adaptive immune responses. Through an unbiased approach, we 
confirm the presence of a type I IFN signature and MHC class 
I antigen presentation across muscle and skin tissues, which is 
consistent with prior studies in DM muscle (35) and skin (3). We 
additionally show a type II IFN signature in both tissues and that 
the majority of the overexpressed ISGs are induced by both type 
I and type II IFNs. This result is consistent with a prior study that 
found that the majority of ISGs expressed in rheumatic diseases 
are induced by both IFN‐α and IFN‐γ in vitro (36). Furthermore, in 
the network analysis, the most significant modules in each tissue 
Figure 6. Heatmaps of cell‐type enrichment calculated using xCell demonstrates clustering of cases and controls based on cell types in both 
muscle (A) and skin (B). Enrichment was strongest for dendritic cells and M1 macrophages in both tissues.
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are enriched in terms related to T‐cell activation and T‐cell recep-
tor signaling. Together, these findings suggest that IFN‐γ signaling 
might contribute to the global IFN signature in DM and that altered 
autoantigen presentation via the class I MHC pathway may play a 
role in disease propagation.
Through computational cell enrichment analysis, we also 
demonstrate an immune infiltrate in both tissues most enriched 
for antigen‐presenting cells, including activated dendritic cells 
and inflammatory M1 macrophages as well as CD4+ and CD8+ 
T cells. These results complement our gene expression findings 
and support the hypothesis that altered autoantigen presentation 
may be a key pathway in DM. Several lines of evidence from prior 
literature support this concept: i) there is early and widespread 
MHC class I presentation on muscle fibers and endothelial cells 
in myositis (37), ii) transgenic MHC class I presentation on muscle 
cells results in spontaneous development of myositis in a mouse 
model (38), and iii) there is increased expression of immunopro-
teasome subunits, dendritic cells, monocytes, and CD8+ T cells 
in peripheral blood and muscle biopsies of patients with myositis 
(39). Future immunohistochemistry and single‐cell analyses will 
be integral to help validate the infiltrating immune cell types and 
behaviors of these cells.
It remains debated whether muscle cells can serve as pro-
fessional antigen‐presenting cells because it is unknown if they 
express co‐stimulatory molecules (40). However, it is possible that 
co‐stimulation could be provided by other antigen‐presenting cells 
in the correct inflammatory milieu. There are also compelling data 
that suggest mechanisms by which autoantigens are continu-
ously generated, including enhanced expression of autoantigens 
in regenerating muscle fibers, suggesting damaged fibers may be 
the source of autoantigens in myositis (41). These authors also 
demonstrated that granzyme B, a proteolytic enzyme released by 
cytotoxic CD8+ T cells, cleaves many autoantigens in systemic 
autoimmune diseases, representing a possible cycle whereby 
effector cells continuously generate more autoantigens (42). Inter-
estingly, the gene encoding granzyme B, GZMB, was a significant 
hub gene in the S1 module from the skin network.
Our finding of an IFN‐γ signature in DM using data‐driven 
methods is a novel finding. This result is supported by work 
from Wong et  al, wherein both IFN‐β and IFN‐γ transcripts 
correlated most strongly with the IFN score in DM skin (3), 
and another recent study demonstrating IFN‐γ transcripts in 
muscle tissue from subjects with JDM (10). These results also 
highlight the difficulty of differentiating types I and II IFN path-
ways, especially in a highly inflammatory milieu, and highlight 
the significant overlap of these signaling pathways on down-
stream gene expression. In addition to enrichment of IFN‐γ sig-
naling seen in the single‐gene and network analyses, we also 
found overexpression of genes classically induced by IFN‐γ, 
including CXCL9, CXCL10, GBP1, and GBP2 as well as the 
presence of M1 macrophages by cell enrichment, which are 
activated by IFN‐γ. Together, this evidence supports the model 
where IFN‐γ signaling contributes to the global IFN signature 
in DM. Because the majority of upregulated ISGs in our data 
have been shown to be stimulated by both type I and type II 
IFN in historical experiments, we hypothesize that these path-
ways converge and synergize in DM. An alternative hypothesis 
is that there is a dynamic IFN response in DM where type I IFN 
signaling is more important in initiating disease and type II IFN 
becomes more prominent during disease propagation. Future 
single‐cell studies will be informative in determining the cell 
types responsible for the IFN signature in DM.
In addition to innate and adaptive immune dysfunction, this 
unbiased analysis also provides evidence for metabolic dysfunc-
tion in DM. In the network analysis, there is evidence of ER stress 
with enrichment of the unfolded protein response, consistent with 
what has been shown in human myositis (37) and in a mouse 
model of myositis (43), providing further evidence that this may 
be an important pathway that causes intrinsic muscle damage in 
myositis. In both tissues, there is enrichment of metabolic path-
ways in the downregulated genes, including oxidative phosphoryl-
ation and either glycolysis (muscle) or fatty acid metabolism (skin), 
suggesting metabolic dysfunction in both tissues. The implica-
tions of this finding in skin is less clear, as repression of fatty acid 
metabolism appears to be a general finding among inflammatory 
skin disorders (3).
This study is strengthened by combining publicly available 
data sets across the most frequently affected tissues in DM—
muscle and skin—which amounts to be the largest global study 
of gene expression across DM using this unbiased methodology. 
Although studies of peripheral blood may be useful for biomarker 
development, focusing on gene expression in target tissues is 
more informative for learning about disease pathophysiology. By 
applying an unbiased and network‐based analysis, we capture 
a robust signal of immune pathways overexpressed in DM and 
detect additional pathways at the systems level not possible to 
appreciate on the single‐gene level. This computational approach 
demonstrates how diverse data sets can be effectively combined 
to study rare autoimmune diseases such as DM.
There are several limitations to this study. The design is 
cross sectional, which only allows for a static view of gene 
expression. Although we demonstrate consistent strong sig-
natures across tissues with identification of 94 overlapping 
genes and enrichment of overlapping immune pathways, the 
study population is inherently heterogeneous, and individual 
clinical data regarding possible confounders, including age, 
sex, disease duration, and treatment status are unavailable to 
include in the analysis. The ability to adjust our analysis for 
these covariates would further strengthen the validity of our 
analysis by normalizing some of the variation in the population 
and minimizing confounding. Additionally, gene expression is 
gauged from bulk tissues, which represent a heterogenous 
population of immune cells rather than the contribution of 
gene expression from individual immune cells. Because data 
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on the degree of inflammatory infiltrate were unavailable, we 
were not able to determine whether our results were attributa-
ble to infiltrating immune cells versus tissue cells. Lastly, gene 
expression studies are a useful discovery tool, but the nature 
of this data type limits the conclusions that can be drawn with 
regards to biology without validating functional studies.
In conclusion, we demonstrate striking similarity in the 
muscle and skin gene expression of DM and presence of both 
type I and II IFN gene signatures, suggesting IFN‐γ signaling 
may be important in disease pathogenesis. Upregulation of 
genes involved in MHC class I antigen‐processing and pres-
entation, T‐cell activation and presence of antigen‐presenting 
cells suggests altered autoantigen presentation and T‐cell 
cytotoxicity may be important pathways in disease propaga-
tion. Given the importance of the immunoproteasome in pro-
cessing class I MHC antigens, immunoproteasome inhibition 
could represent a druggable pathway in DM, as others have 
suggested and mouse work supports (43), and will be an area 
of exciting future research. Longitudinal studies investigating 
changes in the type I and II specific IFN responses and the 
crosstalk between these pathways are also needed to clarify 
potential DM‐specific therapeutic targets. Advances in com-
putational methods and genomic technologies will provide 
a powerful approach to further explore these pathways and 
understand their relevance in DM.
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